<?xml version="1.0" encoding="ISO-8859-15"?>








<rss version="2.0">
    <channel>
        
        <title>Roche Holding AG</title>
        <link>http://www.baltimoresun.com/topic/economy-business-finance/chemicals/pharmaceuticals/roche-holding-ag-ORCRP013215.topic</link>
        
        
        <description>A collection of news and information related to Roche Holding AG published by Tribune Company sources.</description>
        
        <language>en-us</language>
        
        
			
			
				
					
					
					
					
		<item>
			<title><![CDATA[Reuters Health News Summary]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-healthn15198010-20120515,0,2092261.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-05-15 14:01:04</pubDate>
            <description><![CDATA[Following is a summary of current health news briefs.

Insecticide resistance threatens malaria fight

LONDON (Reuters) - Malaria-carrying mosquitoes in Africa
and India are becoming resistant to insecticides, putting
millions of lives at greater risk and...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[Roche Alzheimer's drug picked for major test]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-us-alzheimers-genentechbre84e0uj-20120515,0,7735615.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-05-15 08:15:20</pubDate>
            <description><![CDATA[CHICAGO (Reuters) - Roche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[U.S. may speed approval of 'breakthrough' drugs]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-drugs-breakthroughl1e8g8a89-20120509,0,7893053.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-05-09 05:01:03</pubDate>
            <description><![CDATA[* Companies may do shorter, fewer trials for approval

* Proposal likely to pass as part of FDA user fee bill

By Anna Yukhananov

WASHINGTON, May 9 (Reuters) - Experimental drugs that show a
big effect early in development for treating serious or
life-...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[U.S. may speed approval of "breakthrough" drugs]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-us-drugs-breakthroughbre8480n5-20120509,0,4501284.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-05-09 11:28:03</pubDate>
            <description><![CDATA[WASHINGTON (Reuters) - Experimental drugs that show a big effect early in development for treating serious or life-threatening diseases would get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year.

U.S. drug...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[US STOCKS-Futures edge higher, Apple to report results]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-markets-usa-stocksl2e8fo0us-20120424,0,1840818.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-24 04:32:03</pubDate>
            <description><![CDATA[* Apple to report results after the close

* Netflix slides premarket after forecast

* Futures up: Dow 33 pts, S&P 4.5 pts, Nasdaq 14.5 pts

By Edward Krudy

NEW YORK, April 24 (Reuters) - U.S. stock index futures
crept higher on Tuesday after sharp...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[UPDATE 3-Watson to buy Actavis for at least $5.6 bln]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-watsonactavis--update-3l2e8fph03-20120425,0,2032701.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-25 15:52:02</pubDate>
            <description><![CDATA[* Deal to immediately add to Watson earnings

* Sees more than $300 mln in synergies within three years

* About 40 pct of generic revs to come from outside U.S.

* Shares rise 5.5 percent

(Adds recent deal activity, further details on deal)

By Lewis...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[Watson comprar&#195;&#161; firma gen&#195;&#169;ricos Actavis por 4.250 mln euros]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-farmaceuticas-watsonl2e8fpiz0-20120425,0,6670967.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-25 16:35:07</pubDate>
            <description><![CDATA[Abr 25 (Reuters) - Watson Pharmaceuticals dijo el miércoles
que acordó adquirir Actavis Group por al menos 4.250 millones de
euros (5.600 millones de dólares), en una compra que fortalecerá
su posición como uno de los mayores proveedores de...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[Illumina says holders reject Roche's proposal]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-illuminarocheurgentl2e8fi3xu-20120418,0,2165119.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-18 06:30:09</pubDate>
            <description><![CDATA[April 18 (Reuters) - Illumina Inc said on Wednesday
that its shareholders rejected Roche Holding AG's 
proposal to increase the number of directors to 11, while
backing all four of Illumina's nominees to the board, scuttling
the Swiss drugmaker's...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[MARKET PULSE-US stocks to watch: Chesapeake, Halliburton, Berkshire]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-markets-stocks-headlinesl3e8fi4jj-20120418,0,7729780.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-18 07:29:03</pubDate>
            <description><![CDATA[April 18 (Reuters) - Some U.S. stocks to watch on Wednesday:


CHESAPEAKE ENERGY CORP, $17.80, down 7 pct

Shares of the company fell after a Reuters report that Chief
Executive Aubrey McClendon had borrowed as much as $1.1 billion
over the last three...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[Deals of the day -- mergers and acquisitions]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-mergersdealsl3e8fi3g8-20120418,0,7867808.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-18 12:36:07</pubDate>
            <description><![CDATA[April 18 (Reuters) - The following bids, mergers,
acquisitions and disposals involving European, U.S. and Asian
companies were reported by 2000 GMT on Wednesday:

** Nestle, the world's biggest food group, is
closing in on a deal to buy Pfizer's infant...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[Roche set to drop bid for Illumina]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/la-fi-roche-illumina-20120419,0,2561579.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-19 00:00:00</pubDate>
            <description><![CDATA[Swiss drug maker Roche Holding said it was prepared to walk away from its attempt to take over Illumina Inc. after the San Diego biotech company's shareholders rejected Roche's attempts to appoint new board members.

Roche's current offer of $51 per...]]></description>
		</item>
				
					
					
					
					
		<item>
			<title><![CDATA[UPDATE 3-GSK pounces on Human Genome with $2.6 billion bid]]></title>
			
			

			
			<link>http://www.baltimoresun.com/topic/sns-rt-humangenome-gsk-update-3l6e8fj6hy-20120419,0,4620858.story?track=rss-topicgallery</link>
				
			
			<pubDate>2012-04-19 04:29:02</pubDate>
            <description><![CDATA[* GSK unsolicited offer at $13/share, 81 pct premium

* Human Genome says doesn't reflect value of company

* Shares more than double to $15 in pre-market

* U.S. firm hires Goldman, Credit Suisse to weigh options

(Adds Human Genome shares, comments from...]]></description>
		</item>
				
			
			
        

        
			
        
    </channel>
</rss>


